Celcuity Inc CELC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CELC is a good fit for your portfolio.
News
-
Celcuity To Participate in Jefferies Global Healthcare Conference
-
Celcuity Announces Pricing of Underwritten Common Stock Offering
-
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
-
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
-
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
Trading Information
- Previous Close Price
- $19.15
- Day Range
- $18.60–19.77
- 52-Week Range
- $8.39–22.19
- Bid/Ask
- $16.50 / $19.65
- Market Cap
- $657.44 Mil
- Volume/Avg
- 575,360 / 342,409
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 55
- Website
- https://www.celcuity.com
Comparables
Valuation
Metric
|
CELC
|
ITOS
|
CTIC
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.31 | 1.14 | — |
Price/Sales | — | — | 14.71 |
Price/Cash Flow | — | — | — |
Price/Earnings
CELC
ITOS
CTIC
Financial Strength
Metric
|
CELC
|
ITOS
|
CTIC
|
---|---|---|---|
Quick Ratio | 10.64 | 12.80 | 1.20 |
Current Ratio | 11.23 | 13.51 | 1.27 |
Interest Coverage | −13.89 | — | −3.20 |
Quick Ratio
CELC
ITOS
CTIC
Profitability
Metric
|
CELC
|
ITOS
|
CTIC
|
---|---|---|---|
Return on Assets (Normalized) | −40.23% | −16.56% | −46.52% |
Return on Equity (Normalized) | −56.35% | −18.86% | — |
Return on Invested Capital (Normalized) | −44.81% | −22.78% | −143.40% |
Return on Assets
CELC
ITOS
CTIC
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Gpjwdwzx | Hbhtf | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Yklzwjqd | Zsjfg | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Dwslgdz | Nvpdwb | $118.7 Bil | |||
Moderna Inc
MRNA
| Xscvntzf | Swcx | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Xkqwkybt | Ywqgnmd | $29.7 Bil | |||
argenx SE ADR
ARGX
| Zpdwwpd | Kwlnr | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Gphnwvmb | Bcdl | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Rxptpybm | Lgpslz | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Qfxbdmvk | Qdtb | $15.0 Bil | |||
Incyte Corp
INCY
| Zknvvqyv | Ncpqyq | $13.5 Bil |